TP53 and ovarian cancer: After confirming the ability of our constructs to induce late stage cell death, we focused our attention to two ovarian cancer cell lines, Kuramochi with dominant negative and structural mutant p53 (D281Y) along with the murine ovarian cancer line ID8 (wild type, low expressing p53) [28, 29, 36].